1h Free Analyst Time
The publisher has been monitoring the orthostatic hypotension drugs market and it is poised to grow by $571.76 mn during 2022-2026 progressing at a CAGR of 9.06% during the forecast period. The report on the orthostatic hypotension drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of OH in geriatric population, Increasing prevalence of chronic diseases associated with high risk of OH, and high market growth opportunities for OH drugs in emerging countries.
The orthostatic hypotension drugs market analysis includes the product segment and geographic landscape.
The orthostatic hypotension drugs market is segmented as below:
By Product
- Midodrine
- Northera (droxidopa)
- Fludrocortisone
- Other drugs
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the research and development of new drugs for OH treatment as one of the prime reasons driving the orthostatic hypotension drugs market growth during the next few years. Also, use of combination therapy in oh treatment and adoption of fludrocortisone as off-label first-line pharmacotherapy will lead to sizable demand in the market.
The report on orthostatic hypotension drugs market covers the following areas:
- Orthostatic hypotension drugs market sizing
- Orthostatic hypotension drugs market forecast
- Orthostatic hypotension drugs market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading orthostatic hypotension drugs market vendors that include Alchemy Laboratories Pvt Ltd., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Apotex Inc., Avadel Pharmaceuticals plc, Baxter International Inc., Brancaster Pharma Ltd., Cadila Healthcare Ltd., Cerecor Inc., Enaltec Labs Pvt. Ltd., Endo International Plc, H. Lundbeck AS, Hikma Pharmaceuticals Plc, J B Chemicals and Pharmaceuticals Ltd., Manus Aktteva Biopharma LLP, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., and Viatris Inc. Also, the orthostatic hypotension drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Incremental Growth
Exhibit 07: Executive Summary - Data Table on Incremental Growth
Exhibit 08: Executive Summary - Chart on Vendor Market Positioning
2. Market Landscape
2.1 Market ecosystem
Exhibit 09: Parent market
Exhibit 10: Market Characteristics
3. Market Sizing
3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4. Five Forces Analysis
4.1 Five forces summary
Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
4.2 Bargaining power of buyers
Exhibit 18: Bargaining power of buyers - Impact of key factors in 2021 and 2026
4.3 Bargaining power of suppliers
Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
4.4 Threat of new entrants
Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
4.5 Threat of substitutes
Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
4.6 Threat of rivalry
Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
4.7 Market condition
Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5. Market Segmentation by Product
5.1 Market segments
Exhibit 24: Chart on Product - Market share 2021-2026 (%)
Exhibit 25: Data Table on Product - Market share 2021-2026 (%)
5.2 Comparison by Product
Exhibit 26: Chart on Comparison by Product
Exhibit 27: Data Table on Comparison by Product
5.3 Midodrine - Market size and forecast 2021-2026
Exhibit 28: Chart on Midodrine - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Data Table on Midodrine - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Chart on Midodrine - Year-over-year growth 2021-2026 (%)
Exhibit 31: Data Table on Midodrine - Year-over-year growth 2021-2026 (%)
5.4 Northera (droxidopa) - Market size and forecast 2021-2026
Exhibit 32: Chart on Northera (droxidopa) - Market size and forecast 2021-2026 ($ million)
Exhibit 33: Data Table on Northera (droxidopa) - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Chart on Northera (droxidopa) - Year-over-year growth 2021-2026 (%)
Exhibit 35: Data Table on Northera (droxidopa) - Year-over-year growth 2021-2026 (%)
5.5 Fludrocortisone - Market size and forecast 2021-2026
Exhibit 36: Chart on Fludrocortisone - Market size and forecast 2021-2026 ($ million)
Exhibit 37: Data Table on Fludrocortisone - Market size and forecast 2021-2026 ($ million)
Exhibit 38: Chart on Fludrocortisone - Year-over-year growth 2021-2026 (%)
Exhibit 39: Data Table on Fludrocortisone - Year-over-year growth 2021-2026 (%)
5.6 Other drugs - Market size and forecast 2021-2026
Exhibit 40: Chart on Other drugs - Market size and forecast 2021-2026 ($ million)
Exhibit 41: Data Table on Other drugs - Market size and forecast 2021-2026 ($ million)
Exhibit 42: Chart on Other drugs - Year-over-year growth 2021-2026 (%)
Exhibit 43: Data Table on Other drugs - Year-over-year growth 2021-2026 (%)
5.7 Market opportunity by Product
Exhibit 44: Market opportunity by Product ($ million)
6. Customer Landscape
6.1 Customer landscape overview
Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7. Geographic Landscape
7.1 Geographic segmentation
Exhibit 46: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibit 47: Data Table on Market share By Geographical Landscape 2021-2026 (%)
7.2 Geographic comparison
Exhibit 48: Chart on Geographic comparison
Exhibit 49: Data Table on Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 58: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 59: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 60: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 61: Data Table on Asia - Year-over-year growth 2021-2026 (%)
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
7.7 US - Market size and forecast 2021-2026
Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)
7.8 Canada - Market size and forecast 2021-2026
Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
7.9 Germany - Market size and forecast 2021-2026
Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
7.10 China - Market size and forecast 2021-2026
Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%)
7.11 UK - Market size and forecast 2021-2026
Exhibit 82: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 83: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 84: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibit 85: Data Table on UK - Year-over-year growth 2021-2026 (%)
7.12 Market opportunity By Geographical Landscape
Exhibit 86: Market opportunity By Geographical Landscape ($ million)
8. Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
Exhibit 87: Impact of drivers and challenges in 2021 and 2026
8.4 Market trends
9. Vendor Landscape
9.1 Overview
9.2 Vendor landscape
Exhibit 88: Overview on Criticality of inputs and Factors of differentiation
9.3 Landscape disruption
Exhibit 89: Overview on factors of disruption
9.4 Industry risks
Exhibit 90: Impact of key risks on business
10. Vendor Analysis
10.1 Vendors covered
Exhibit 91: Vendors covered
10.2 Market positioning of vendors
Exhibit 92: Matrix on vendor position and classification
10.3 Amneal Pharmaceuticals Inc.
Exhibit 93: Amneal Pharmaceuticals Inc. - Overview
Exhibit 94: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 95: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 96: Amneal Pharmaceuticals Inc. - Segment focus
10.4 Apotex Inc.
Exhibit 97: Apotex Inc. - Overview
Exhibit 98: Apotex Inc. - Product / Service
Exhibit 99: Apotex Inc. - Key offerings
10.5 Avadel Pharmaceuticals plc
Exhibit 100: Avadel Pharmaceuticals plc - Overview
Exhibit 101: Avadel Pharmaceuticals plc - Business segments
Exhibit 102: Avadel Pharmaceuticals plc - Key news
Exhibit 103: Avadel Pharmaceuticals plc - Key offerings
Exhibit 104: Avadel Pharmaceuticals plc - Segment focus
10.6 Baxter International Inc.
Exhibit 105: Baxter International Inc. - Overview
Exhibit 106: Baxter International Inc. - Business segments
Exhibit 107: Baxter International Inc. - Key offerings
Exhibit 108: Baxter International Inc. - Segment focus
10.7 Endo International Plc
Exhibit 109: Endo International Plc - Overview
Exhibit 110: Endo International Plc - Business segments
Exhibit 111: Endo International Plc - Key news
Exhibit 112: Endo International Plc - Key offerings
Exhibit 113: Endo International Plc - Segment focus
10.8 H. Lundbeck AS
Exhibit 114: H. Lundbeck AS - Overview
Exhibit 115: H. Lundbeck AS - Business segments
Exhibit 116: H. Lundbeck AS - Key offerings
Exhibit 117: H. Lundbeck AS - Segment focus
10.9 Novartis AG
Exhibit 118: Novartis AG - Overview
Exhibit 119: Novartis AG - Business segments
Exhibit 120: Novartis AG - Key offerings
Exhibit 121: Novartis AG - Segment focus
10.10 Pfizer Inc.
Exhibit 122: Pfizer Inc. - Overview
Exhibit 123: Pfizer Inc. - Business segments
Exhibit 124: Pfizer Inc. - Key news
Exhibit 125: Pfizer Inc. - Key offerings
Exhibit 126: Pfizer Inc. - Segment focus
10.11 Teva Pharmaceutical Industries Ltd.
Exhibit 127: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 128: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 129: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 130: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 131: Teva Pharmaceutical Industries Ltd. - Segment focus
10.12 Viatris Inc.
Exhibit 132: Viatris Inc. - Overview
Exhibit 133: Viatris Inc. - Business segments
Exhibit 134: Viatris Inc. - Key offerings
Exhibit 135: Viatris Inc. - Segment focus
11. Appendix
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
Exhibit 136: Inclusions checklist
Exhibit 137: Exclusions checklist
11.3 Currency conversion rates for US$
Exhibit 138: Currency conversion rates for US$
11.4 Research methodology
Exhibit 139: Research methodology
Exhibit 140: Validation techniques employed for market sizing
Exhibit 141: Information sources
11.5 List of abbreviations
Exhibit 142: List of abbreviations
List of ExhibitsExhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Product
Exhibits 6: Executive Summary - Chart on Incremental Growth
Exhibits 7: Executive Summary - Data Table on Incremental Growth
Exhibits 8: Executive Summary - Chart on Vendor Market Positioning
Exhibits 9: Parent market
Exhibits 10: Market Characteristics
Exhibits 11: Offerings of vendors included in the market definition
Exhibits 12: Market segments
Exhibits 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 17: Five forces analysis - Comparison between 2021 and 2026
Exhibits 18: Bargaining power of buyers - Impact of key factors in 2021 and 2026
Exhibits 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
Exhibits 20: Threat of new entrants - Impact of key factors in 2021 and 2026
Exhibits 21: Threat of substitutes - Impact of key factors in 2021 and 2026
Exhibits 22: Threat of rivalry - Impact of key factors in 2021 and 2026
Exhibits 23: Chart on Market condition - Five forces 2021 and 2026
Exhibits 24: Chart on Product - Market share 2021-2026 (%)
Exhibits 25: Data Table on Product - Market share 2021-2026 (%)
Exhibits 26: Chart on Comparison by Product
Exhibits 27: Data Table on Comparison by Product
Exhibits 28: Chart on Midodrine - Market size and forecast 2021-2026 ($ million)
Exhibits 29: Data Table on Midodrine - Market size and forecast 2021-2026 ($ million)
Exhibits 30: Chart on Midodrine - Year-over-year growth 2021-2026 (%)
Exhibits 31: Data Table on Midodrine - Year-over-year growth 2021-2026 (%)
Exhibits 32: Chart on Northera (droxidopa) - Market size and forecast 2021-2026 ($ million)
Exhibits 33: Data Table on Northera (droxidopa) - Market size and forecast 2021-2026 ($ million)
Exhibits 34: Chart on Northera (droxidopa) - Year-over-year growth 2021-2026 (%)
Exhibits 35: Data Table on Northera (droxidopa) - Year-over-year growth 2021-2026 (%)
Exhibits 36: Chart on Fludrocortisone - Market size and forecast 2021-2026 ($ million)
Exhibits 37: Data Table on Fludrocortisone - Market size and forecast 2021-2026 ($ million)
Exhibits 38: Chart on Fludrocortisone - Year-over-year growth 2021-2026 (%)
Exhibits 39: Data Table on Fludrocortisone - Year-over-year growth 2021-2026 (%)
Exhibits 40: Chart on Other drugs - Market size and forecast 2021-2026 ($ million)
Exhibits 41: Data Table on Other drugs - Market size and forecast 2021-2026 ($ million)
Exhibits 42: Chart on Other drugs - Year-over-year growth 2021-2026 (%)
Exhibits 43: Data Table on Other drugs - Year-over-year growth 2021-2026 (%)
Exhibits 44: Market opportunity by Product ($ million)
Exhibits 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 46: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 47: Data Table on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 48: Chart on Geographic comparison
Exhibits 49: Data Table on Geographic comparison
Exhibits 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 52: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibits 53: Data Table on North America - Year-over-year growth 2021-2026 (%)
Exhibits 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 58: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits 59: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits 60: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibits 61: Data Table on Asia - Year-over-year growth 2021-2026 (%)
Exhibits 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits 66: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibits 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibits 68: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibits 69: Data Table on US - Year-over-year growth 2021-2026 (%)
Exhibits 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibits 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibits 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibits 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
Exhibits 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibits 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
Exhibits 78: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibits 79: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibits 80: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibits 81: Data Table on China - Year-over-year growth 2021-2026 (%)
Exhibits 82: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibits 83: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibits 84: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibits 85: Data Table on UK - Year-over-year growth 2021-2026 (%)
Exhibits 86: Market opportunity By Geographical Landscape ($ million)
Exhibits 87: Impact of drivers and challenges in 2021 and 2026
Exhibits 88: Overview on Criticality of inputs and Factors of differentiation
Exhibits 89: Overview on factors of disruption
Exhibits 90: Impact of key risks on business
Exhibits 91: Vendors covered
Exhibits 92: Matrix on vendor position and classification
Exhibits 93: Amneal Pharmaceuticals Inc. - Overview
Exhibits 94: Amneal Pharmaceuticals Inc. - Business segments
Exhibits 95: Amneal Pharmaceuticals Inc. - Key offerings
Exhibits 96: Amneal Pharmaceuticals Inc. - Segment focus
Exhibits 97: Apotex Inc. - Overview
Exhibits 98: Apotex Inc. - Product / Service
Exhibits 99: Apotex Inc. - Key offerings
Exhibits 100: Avadel Pharmaceuticals plc - Overview
Exhibits 101: Avadel Pharmaceuticals plc - Business segments
Exhibits 102: Avadel Pharmaceuticals plc - Key news
Exhibits 103: Avadel Pharmaceuticals plc - Key offerings
Exhibits 104: Avadel Pharmaceuticals plc - Segment focus
Exhibits 105: Baxter International Inc. - Overview
Exhibits 106: Baxter International Inc. - Business segments
Exhibits 107: Baxter International Inc. - Key offerings
Exhibits 108: Baxter International Inc. - Segment focus
Exhibits 109: Endo International Plc - Overview
Exhibits 110: Endo International Plc - Business segments
Exhibits 111: Endo International Plc - Key news
Exhibits 112: Endo International Plc - Key offerings
Exhibits 113: Endo International Plc - Segment focus
Exhibits 114: H. Lundbeck AS - Overview
Exhibits 115: H. Lundbeck AS - Business segments
Exhibits 116: H. Lundbeck AS - Key offerings
Exhibits 117: H. Lundbeck AS - Segment focus
Exhibits 118: Novartis AG - Overview
Exhibits 119: Novartis AG - Business segments
Exhibits 120: Novartis AG - Key offerings
Exhibits 121: Novartis AG - Segment focus
Exhibits 122: Pfizer Inc. - Overview
Exhibits 123: Pfizer Inc. - Business segments
Exhibits 124: Pfizer Inc. - Key news
Exhibits 125: Pfizer Inc. - Key offerings
Exhibits 126: Pfizer Inc. - Segment focus
Exhibits 127: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits 128: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits 129: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits 130: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits 131: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits 132: Viatris Inc. - Overview
Exhibits 133: Viatris Inc. - Business segments
Exhibits 134: Viatris Inc. - Key offerings
Exhibits 135: Viatris Inc. - Segment focus
Exhibits 136: Inclusions checklist
Exhibits 137: Exclusions checklist
Exhibits 138: Currency conversion rates for US$
Exhibits 139: Research methodology
Exhibits 140: Validation techniques employed for market sizing
Exhibits 141: Information sources
Exhibits 142: List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global orthostatic hypotension drugs market: Alchemy Laboratories Pvt Ltd., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Apotex Inc., Avadel Pharmaceuticals plc, Baxter International Inc., Brancaster Pharma Ltd., Cadila Healthcare Ltd., Cerecor Inc., Enaltec Labs Pvt. Ltd., Endo International Plc, H. Lundbeck AS, Hikma Pharmaceuticals Plc, J B Chemicals and Pharmaceuticals Ltd., Manus Aktteva Biopharma LLP, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., and Viatris Inc.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is research and development of new drugs for OH treatment.`
According to the report, one of the major drivers for this market is the increasing prevalence of OH in geriatric population.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alchemy Laboratories Pvt Ltd.
- Alembic Pharmaceuticals Ltd.
- Amneal Pharmaceuticals Inc.
- Apotex Inc.
- Avadel Pharmaceuticals plc
- Baxter International Inc.
- Brancaster Pharma Ltd.
- Cadila Healthcare Ltd.
- Cerecor Inc.
- Enaltec Labs Pvt. Ltd.
- Endo International Plc
- H. Lundbeck AS
- Hikma Pharmaceuticals Plc
- J B Chemicals and Pharmaceuticals Ltd.
- Manus Aktteva Biopharma LLP
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Theravance Biopharma Inc.
- Viatris Inc.
